New drug combo aims to shrink tough lung tumors

NCT ID NCT05904379

Ongoing Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two experimental immunotherapy drugs, AK112 and AK104, given together with or without standard chemotherapy. The goal is to see if this combination can safely shrink tumors and control advanced non-small cell lung cancer. About 233 adults with stage IIIB/IV lung cancer who cannot have curative treatment are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AK112 and AK104 (immunotherapy drugs), with or without chemotherapy (carboplatin, paclitaxel, pemetrexed, or docetaxel)
What this could lead to: If successful, this combination could offer a new treatment option that helps shrink tumors and control advanced lung cancer for longer.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to all patients. Side effects from immunotherapy and chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Pulmonary Hospital

Shanghai, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.